Aptinyx stung by pain drug's mid-stage miss

Aptinyx, an Illinois-based biotech, saw its share value dive roughly 70% Wednesday morning after announcing its lead candidate failed a Phase 2 study of patients with painful diabetic peripheral neuropathy.